成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Stem Cell/Wnt Apoptosis Autophagy
  3. YAP Apoptosis Autophagy
  4. Verteporfin

Verteporfin  (Synonyms: 維替泊芬; CL 318952)

目錄號(hào): HY-B0146 純度: 99.26%
COA 產(chǎn)品使用指南 技術(shù)支持

Verteporfin (CL 318952) 是一種用于光動(dòng)力療法的光敏劑，用于消除與年齡相關(guān)的黃斑變性等疾病相關(guān)的眼內(nèi)異常血管。 Verteporfin 是一種 YAP 抑制劑，可破壞 YAP-TEAD 相互作用。Verteporfin 可以誘導(dǎo)細(xì)胞凋亡 (apoptosis)。Verteporfin 是一種自噬 (autophagy) 抑制劑，通過(guò)抑制自噬小體形成，在早期阻斷自噬。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Verteporfin Chemical Structure

Verteporfin Chemical Structure

CAS No. : 129497-78-5

1.  客戶(hù)無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶(hù)。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥1297
In-stock
5 mg ￥990
In-stock
10 mg ￥1520
In-stock
50 mg ￥5800
In-stock
100 mg 現(xiàn)貨 詢(xún)價(jià)
200 mg   詢(xún)價(jià)  
500 mg   詢(xún)價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Verteporfin:

MCE 顧客使用本產(chǎn)品發(fā)表的 183 篇科研文獻(xiàn)

WB
IHC
IF
RT-PCR
Proliferation Assay
Cell Viability Assay

    Verteporfin purchased from MCE. Usage Cited in: J Transl Med. 2023 Apr 1;21(1):238.  [Abstract]

    Verteporfin (13.9 μM; 10 μg/mL; 24 h) decreases the expression of YAP and CDX2 in NSCCs.

    Verteporfin purchased from MCE. Usage Cited in: Reprod Sci. 2023 Mar 20.  [Abstract]

    Verteporfin (0-5 μM; 24 h) decreases the viability of Ishikawa cells in a concentration-dependent manner (IC50 = 1.345 μM).

    Verteporfin purchased from MCE. Usage Cited in: Reprod Sci. 2023 Mar 20.  [Abstract]

    Verteporfin (0.5, 1, 2 μM) decreases the expression of anti-apoptotic marker B cell leukemia 2 (Bcl2), while increases the expression of pro-apoptotic protein Bcl2-associated X protein (Bax) in Ishikawa cells, in a concentration-dependent manner.

    Verteporfin purchased from MCE. Usage Cited in: Cell Res. 2022 Jun;32(6):543-554.  [Abstract]

    Survival of mice with striatal GL261 tumor injection with or without RT, saline plus laser treatment, or Verteporfin (Visudyne; 2?mg/mL; 5?μL was injected into the cisterna magna; 15?min) plus laser treatment.

    Verteporfin purchased from MCE. Usage Cited in: Nat Neurosci. 2022 Jul;25(7):849-864.  [Abstract]

    Verteporfin (1?μM)-treated animals exposed to 640?nm in the head exhibits less mrc1a+ cells in the brain compared to non-photoactivated control animals.

    Verteporfin purchased from MCE. Usage Cited in: Nat Commun. 2022 Oct 5;13(1):5871.  [Abstract]

    Mice are injected with either Verteporfin (VP; 100?mg/kg) or vehicle (corn oil) from the postnatal 7 days at 3-day intervals for 14 days. The immunohistochemical assay shows that the expression of TFRC and COX2 is higher in Bnc1tr/tr control mouse ovaries than in Bnc1+/+ control mouse ovaries. Intriguingly, VP treatment partially rescues TFRC and COX2 expression in Bnc1tr/tr mouse ovaries.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 μM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    The protective effects of TNIP3 against cell inflammation and cell death were largely abolished by Verteporfin (VP; 100 μM) administration.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 μM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    The expression levels of Hippo-YAP signaling downstream regenerative genes (Ctgf, Ankrd1 and Cyr61) are effectively inhibited by Verteporfin (VP; 100 μM) compared to their expression in the blank control group.

    Verteporfin purchased from MCE. Usage Cited in: Cell Res. 2020 Mar;30(3):229-243.  [Abstract]

    The representative images of dCLNs and sCLNs 2 weeks after striatal injection of GL261 or B16 cells into mice treated with Vehicle?+?Laser or =Verteporfin (Visudyne; 2?mg/mL; 5?μL was injected into the cisterna magna; 15?min)?+?Laser.

    Verteporfin purchased from MCE. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936.  [Abstract]

    Protoporphyrin IX and Verteporfin effectively prevent SARS-CoV-2 infection in the mouse model expressing human ACE2. Much fewer cells expressed viral N protein in the Protoporphyrin IX and Verteporfin (20 μM) groups compared to the DMSO group.

    Verteporfin purchased from MCE. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936.  [Abstract]

    Verteporfin displays a complete suppression of viral CPE at 0.31 μM. Viral N protein expression in infected Vero E6 cells was assessed by immunofluorescence.

    Verteporfin purchased from MCE. Usage Cited in: Cancer Cell. 2019 Sep 16;36(3):302-318.e7.  [Abstract]

    Combined treatment of GFAP-Ptch tumor cells with Verteporfin (VP; 24 hours) and CD532 additively decreases proliferation of ZIC1+ tumor cells relative to individual treatments.

    Verteporfin purchased from MCE. Usage Cited in: Mol Cell. 2019 Jan 3;73(1):7-21.e7.  [Abstract]

    Control low metastatic MDA-MB-231 cells or cells overexpressing OTUB2-WT, pretreated with or without Verteporfin (VP, 10 μM) are intracardially injected into nude mice.

    Verteporfin purchased from MCE. Usage Cited in: Mol Immunol. 2019 Mar;107:29-40.  [Abstract]

    Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.

    Verteporfin purchased from MCE. Usage Cited in: Mol Immunol. 2019 Mar;107:29-40.  [Abstract]

    Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.

    Verteporfin purchased from MCE. Usage Cited in: Front Cell Neurosci. 2018 Dec 11;12:489.  [Abstract]

    OECs are treated with vehicle (0.1% DMSO), Y27632 (10 μM) or verteporfin (5 μM) for 24 h and performed WB analysis.

    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks?autophagy?at an early stage by inhibiting autophagosome formation[3].

    IC50 & Target

    IC50: YAP-TEAD interaction
    體外研究
    (In Vitro)

    Verteporfin 是通過(guò) PDX 細(xì)胞篩選特別選擇的。PhLO、PhLH 和 PhLK 引起 50% 生長(zhǎng)抑制 (GI50) 的濃度分別為 228 nM、395 nM 和 538 nM，而 GI50 ALL-1、TCC-Y/sr 和 NPhA1 分別為 3.93 μM、2.11 μM 和 5.61 μM。GSH 顯著降低了 3 個(gè) PDX 細(xì)胞中的 2 個(gè)對(duì) Verteporfin 的敏感性。Verteporfin 降低 PDX 細(xì)胞中的線(xiàn)粒體膜電位[1]。Verteporfin 通過(guò)抑制 YAP 表達(dá)降低 HCT-8/T 細(xì)胞的 PTX 耐藥性，與 Verteporfin 聯(lián)合處理和 NSC 125973 顯示出抑制 YAP 和對(duì) HCT-8/T 的細(xì)胞毒性的協(xié)同作用[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    Verteporfin (10 mg/kg，c.s.c.) 和 BMS-354825 顯著降低了白血病細(xì)胞比例，聯(lián)合處理進(jìn)一步降低了脾臟中白血病細(xì)胞的數(shù)量[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    718.79

    Formula

    C41H42N4O8
    CAS 號(hào)
    性狀

    固體

    顏色

    Brown to black

    中文名稱(chēng)

    維替泊芬
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 50 mg/mL (69.56 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

    DMF 中的溶解度 : 10 mg/mL (13.91 mM; 超聲助溶 (<60°C))

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.3912 mL 6.9561 mL 13.9123 mL
    5 mM 0.2782 mL 1.3912 mL 2.7825 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (6.96 mM); 澄清溶液

      此方案可獲得 ≥ 5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 50.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (6.96 mM); 澄清溶液

      此方案可獲得 ≥ 5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 50.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

    • 方案 一

      請(qǐng)依序添加每種溶劑： 50% PEG300    50% Saline

      Solubility: 1 mg/mL (1.39 mM); 懸濁液; 超聲助溶

    • 方案 二

      請(qǐng)依序添加每種溶劑： 15% Cremophor EL    85% Saline

      Solubility: 10 mg/mL (13.91 mM); 懸濁液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.58%

    參考文獻(xiàn)
    Cell Assay
    [1]

    PDX cells co-cultured with S17 cells are treated with 16 combinations of verteporfin (60 nM, 120 nM, 180 nM, and 240 nM) and BMS-354825 (12 nM, 24 nM, 36 nM, and 48 nM). The viabilities of cells treated with each combination are measured after 48 h using FACS Aria flow cytometer. In order to estimate drug interaction between verteporfin and BMS-354825, a normalized isobologram and fraction affectedcombination index (CI) plot are made using CompuSyn software. CI values greater than 1.0 indicated antagonistic effects, equal to 1.0 additive effects, and below 1.0 synergistic effects.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice: PhLO cells (1.0×107/mouse) are injected intravenously into 6-week-old male NOG mice, which are then treated with vehicle, verteporfin (140 mg/kg/day), BMS-354825 (20 mg/kg/day), and a combination of these drugs from days 22 to 28. Verteporfin is administered by continuous subcutaneous infusion (c.s.c.) using Alzet osmotic pumps. An intraperitoneal injection (i.p.) is performed for BMS-354825. All mice are sacrificed on day 28 and the chimerism of leukemia cells is investigated by flow cytometer using an anti-human CD19 antibody and antimouse CD45 antibody. Blood concentrations of verteporfin are calculated by LCMS-2020.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMF / DMSO 1 mM 1.3912 mL 6.9561 mL 13.9123 mL 34.7807 mL
    5 mM 0.2782 mL 1.3912 mL 2.7825 mL 6.9561 mL
    10 mM 0.1391 mL 0.6956 mL 1.3912 mL 3.4781 mL
    DMSO 15 mM 0.0927 mL 0.4637 mL 0.9275 mL 2.3187 mL
    20 mM 0.0696 mL 0.3478 mL 0.6956 mL 1.7390 mL
    25 mM 0.0556 mL 0.2782 mL 0.5565 mL 1.3912 mL
    30 mM 0.0464 mL 0.2319 mL 0.4637 mL 1.1594 mL
    40 mM 0.0348 mL 0.1739 mL 0.3478 mL 0.8695 mL
    50 mM 0.0278 mL 0.1391 mL 0.2782 mL 0.6956 mL
    60 mM 0.0232 mL 0.1159 mL 0.2319 mL 0.5797 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱(chēng)：

    		  

    * 需求量：

    * 客戶(hù)姓名：

    		 

    * Email：

    * 電話(huà)：

    		 

    * 公司或機(jī)構(gòu)名稱(chēng)：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱(chēng)：
    Verteporfin
    目錄號(hào)：
    HY-B0146
    需求量：